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N-terminal acetylation of proteins is a widespread and highly conserved process. Aminoacylase 1 (ACY1; EC 3.5.14)
is the most abundant of the aminoacylases, a class of enzymes involved in hydrolysis of N-acetylated proteins.
Here, we present four children with genetic deﬁciency of ACY1. They were identiﬁed through organic acid analyses
using gas chromatography–mass spectrometry, revealing increased urinary excretion of several N-acetylated amino
acids, including the derivatives of methionine, glutamic acid, alanine, leucine, glycine, valine, and isoleucine.Nuclear
magnetic resonance spectroscopy analysis of urine samples detected a distinct pattern of N-acetylated metabolites,
consistent with ACY1 dysfunction. Functional analyses of patients’ lymphoblasts demonstrated ACY1 deﬁciency.
Mutation analysis uncovered recessive loss-of-function or missense ACY1 mutations in all four individuals affected.
We conclude that ACY1 mutations in these children led to functional ACY1 deﬁciency and excretion of N-acetylated
amino acids. Questions remain, however, as to the clinical signiﬁcance of ACY1 deﬁciency. The ACY1-deﬁcient
individuals were ascertained through urine metabolic screening because of unspeciﬁc psychomotor delay (one
subject), psychomotor delay with atrophy of the vermis and syringomyelia (one subject), markedmuscular hypotonia
(one subject), and follow-up for early treated biotinidase deﬁciency and normal clinical ﬁndings (one subject).
Because ACY1 is evolutionarily conserved in ﬁsh, frog, mouse, and human and is expressed in the central nervous
system (CNS) in human, a role in CNS function or development is conceivable but has yet to be demonstrated.
Thus, at this point, we cannot state whether ACY1 deﬁciency has pathogenic signiﬁcance with pleiotropic clinical
expression or is simply a biochemical variant. Awareness of this new genetic entity may help both in delineating
its clinical signiﬁcance and in avoiding erroneous diagnoses.
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N-terminal acetylation of proteins is a widespread and
highly conserved process that is involved in protection
and stability of proteins (Polevoda and Sherman 2000).
Although the biosynthetic pathways leading to acety-
lated amino acids are well studied, less attention has
been paid to the catabolism of N-acetylated peptides.
N-acetylated amino acids can be released by an N-acyl-
peptide hydrolase from peptides generated by proteo-
lytic degradation (Perrier et al. 2005). Several types of
aminoacylases can be distinguished on the basis of sub-
strate speciﬁcity. Aminoacylase 1 (ACY1; EC 3.5.1.14),
the most abundant type, is a soluble homodimeric zinc-
binding enzyme that catalyzes the formation of free al-
iphatic amino acids from N-acetylated precursors (ﬁg.
1). It is encoded by the aminoacylase 1 gene (ACY1) on
chromosome 3p21 that comprises 15 exons (Naylor et
al. 1979, 1982; Miller et al. 1990; Cook et al. 1993).
ACY1 activity was discovered as early as 1881, when
Schmiedeberg coined the name “Histozym” (tissue en-
zyme) for an intracellular enzymatic activity catalyz-
ing the hydrolysis of N-benzoylglycine (hippuric acid)
(Schmiedeberg 1881). In 1922, Smorodinzew reported
on ACY1-catalyzed hydrolysis of various acylated ami-
no acids (Smorodinzew 1922). Preferred substrates of
ACY1 are aliphatic amino acids with a short-chain acyl
moiety, especially N-acetyl-methionine (Birnbaum et al.
1952). However, ACY1 can also catalyze the reverse
reaction, the synthesis of acetylated amino acids (Lind-
ner et al. 2000).
Although deﬁciency of aminoacylase 2 (ACY2, as-
partoacylase; EC 3.5.1.15), which catalyzes the hy-
drolysis of N-acetyl-aspartate to aspartate and ace-
tate, causes Canavan disease (MIM 271900) (Kaul et
al. 1993; Baslow and Resnik 1997), deﬁciency of ACY1
in humans has not been reported so far. The clinical
features of Canavan disease comprise progressive psy-
chomotor regression and muscular hypotonia, enlarged
head, spasticity, severe visual impairment, and death in
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Figure 1 A, Deacetylation of N-acetylamino acids that is catalyzed by ACY1. For and , the N-acetylamino′R p (CH ) SCH R p CH2 2 3 3
acid is N-acetylmethionine, a preferred substrate of ACY1. B and C, Organic acids detected by GC-MS in the urine from (B) a patient (OS-
104 II-1) with ACY1 deﬁciency and (C) a parent as a control. Abbreviations used for peak labels are as follows: ME p methyl ester; IS p
internal standard (isopropylmalonic acid diME); 1 p N-acetylalanine ME; 2 p N-acetylvaline ME; 3 p N-acetylisoleucine ME; 4 p N-
acetylglycine ME; 5 p N-acetylleucine ME; 6 p N-acetylmethionine ME, 7 p N-acetylglutamic acid diME. Consistent with lack of enzymatic
deacetylation, the urinary concentrations of N-acetylamino acids are increased in the ACY1-deﬁcient individual.
early childhood (Canavan 1931; Gordon 2001). Diag-
nosis is based on abnormally high excretion of N-ace-
tylaspartic acid in urine and on enzyme and mutation
analyses.
Here, we report on four children who were found to
excrete signiﬁcant amounts of distinct N-acetylated
amino acids, including the derivatives of methionine,
glutamine, alanine, leucine, glycine, valine, and isoleu-
cine, as determined by gas chromatography–mass spec-
trometry (GC-MS) analysis for organic acids. The chil-
dren had ACY1 deﬁciency in their cultured cells,
providing evidence of a “new” inborn error of metab-
olism. Nuclear magnetic resonance (NMR) spectroscopy
performed on the urine of the patients conﬁrmed a pat-
tern of N-acetylated metabolites consistent with a deﬁ-
ciency in aminoacylase 1, which was demonstrated by
an enzyme activity test in Epstein-Barr virus (EBV)–
transformed lymphoblasts. In all four families, mutation
analysis identiﬁed recessive ACY1 mutations that seg-
regated with the disease status.
Methods
Patients
Clinical histories and ﬁndings, as well as family histories,
of patients with increased excretion of urine metabolites sug-
gestive of defective aminoacylase 1 function were obtained
from medical records.
Metabolite Identiﬁcation and Quantitation
Organic acids, including N-acetylated amino acids, were de-
termined by GC-MS following liquid extraction from urine
and derivatization with diazomethane, as is done on a daily
basis for the identiﬁcation of individuals with inborn errors
of metabolism (Lehnert 1994). Amino acid analysis was per-
formed on Biochrom and Biotronik amino acid analyzers by
use of derivatization with ninhydrine, which reacts with pri-
mary (nonacetylated) amino groups. NMR spectroscopy of
body ﬂuids was performed as described elsewhere (Engelke et
al. 2004). N-acetylated amino acid compounds were either
purchased from Sigma or from the University of Nijmegen or
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were prepared at the Freiburg University Children’s Hospital
Laboratory of Metabolism.
Enzyme Assays
Enzymatic activity of ACY1 was determined in 13,000 g
supernatant obtained from homogenized EBV-transformed
lymphoblasts. Saline-washed cell pellets were homogenized by
ultrasound in 50 mM Tris-HCl buffer (pH 8.0) containing 5
mM ZnCl2 (Giardina et al. 1997) and 0.1% (w/v) Triton X-
100 after they had undergone one freeze-thaw cycle. ACY1
activity was assessed by incubating the 13,000 g supernatant
prepared from the homogenate with ACY1’s high-afﬁnity sub-
strate N-acetylmethionine (dissolved in 0.1 M HEPES buffer,
pH 8.0, according to the recommendation of Giardina et al.
[1997]) at a ﬁnal concentration of 20 mM at 37C. Aliquots
were removed from the incubation mixture at multiple time
points between 0 and 120 min. They were spotted onto ﬁlter-
paper cards (Schleicher & Schuell 903 paper) that were im-
mediately frozen at 80C to stop the reaction. Methionine
concentrations were subsequently determined by tandem mass
spectrometry, and their increase over the time was used to
calculate ACY1 activity. Patient samples were analyzed at least
in duplicate, and the data presented here are the respective
mean values. Protein concentrations were determined by use
of the Lowry method (with BSA as the standard) (Lowry et
al. 1951).
Mutation Analysis
DNA from the four individuals excreting N-acetylamino ac-
ids was screened for the presence of mutations in ACY1. To
this purpose, blood samples were obtained after informed
consent, and genomic DNA was isolated either directly from
blood samples or after EBV transformation of peripheral
blood lymphocytes by use of the QiaAmp Blood sample kit
(Qiagen). The intron-exon structure of ACY1 was obtained by
alignment of cDNA (GenBank accession number BC014112)
and genomic (GenBank accession number NT_022517.17) se-
quences. Exons and the corresponding intron-exon boundaries
of ACY1 were ampliﬁed by PCR with the following primers:
Ex1_f, ACCTCGCTGGACCCTAAGTC; Ex1_r, AGCCCCA-
GTCCCTCTATCC; Ex2_f, CACGGTATCCTACCCCTG-
TG; Ex2_r, TACTTGGGGAATGGCTGGAG; Ex34_f, CT-
GGGTATGCTCCACTCTCC; Ex34_r, GGACCATGAG-
CAACTTGAGG; Ex5_f, ACCACTCCACCTGTCACTCC;
Ex5_r, TCCTTGGCCTTGAGTTTCTC; Ex6–8_f, GGGT-
AAAGTCCAGGACACAGG; Ex6–8_r, CTCAACTTTGCT-
GTGCAACC; Ex910_f, AGAGGAGCCTGGAATGAGG;
Ex910_r, GCGGCAGCAACAGATAAAAG; Ex1112_f,
GGCGGTACCACAGAGGATAG; Ex1112_r, AATGCCCA-
GACATATGCAGAC; Ex1314_f, TGTACTAGGCACAGC-
CCACTC; Ex1314_r, AAGAGCCGTTAGGGAAAAGC;
Ex15_f, ATATAGTGCCTGGGCAGTGG; Ex15_r, GGCTG-
GATGGTACTGAATGG. Product sizes were as follows: exon
1, 117 bp; exon 2, 373 bp; exons 34, 437 bp; exon 5, 312
bp; exons 6–8, 603 bp; exons 910, 401 bp; exons 1112,
494 bp; exons 1314, 458 bp; and exon 15, 541 bp. PCR
was performed in a total volume of 50 ml containing PCR1#
buffer (including 1.5 mM MgCl2), 30 pmol primers, 2 mM
dNTPs, 30 ng template DNA, and 1.5 U Thermus aquaticus
DNA polymerase (Qiagen). Ampliﬁcation was performed with
denaturation at 94C for 4 min followed by 33 cycles of 30 s
at 94C, 30 s of annealing (exons 1, 34, 5, 6–8, 910, and
15 at 63C; exon 2 at 65C; exons 1112 at 59.5C; and
exons 1314 at 63.5C), and 60 s at 72C. Final extension
was performed at 72C for 10 min. Q-Solution was added to
all PCR reactions. Products were bidirectionally sequenced us-
ing the Big-Dye Terminator Kit (PE Applied Biosystems [ABI])
on an ABI capillary sequencer. Data were evaluated with the
CodonCode Aligner sequence analysis software (CodonCode).
By use of allele-speciﬁc restriction analysis and denaturing
high-performance liquid chromatography, 210 control chro-
mosomes were screened for missense mutations.
Northern Blot Analysis
Tissue speciﬁcity of expression of the human ACY1
gene was analyzed by northern blot hybridization, by use
of a 657-bp BsmI/ScaI fragment of the human cDNA
(IMAGp958G107Q [RZPD Web site]) as a probe. Human
multiple-tissue northern blots (BioChain Institute and BD Bio-
sciences) were hybridized overnight at 63.5C in Church buffer
(500 mM phosphate buffer pH 7.2, 7% SDS [w/v], and 1 mM
EDTA supplemented with 100 mg/ml salmon sperm DNA).
The ACY1-speciﬁc probe was radiolabeled with a-32P-dCTP
(Amersham) by use of a Megaprime DNA labeling kit (Amer-
sham). Filters were rinsed twice at room temperature with
saline sodium citrate (SSC)/0.1% SDS and were washed2#
once for 10 min with SSC/0.1% SDS. Membranes were0.2#
exposed to BioMax MS ﬁlms (Kodak) in the presence of an
intensifying screen.
Results
Metabolite Analyses
GC-MS analysis identiﬁed four individuals with a pat-
tern of urinary organic acids dominated by high signals
of several N-acetylated amino acids, including deriva-
tives of methionine, glutamic acid, alanine, valine,
glycine, leucine, and isoleucine (ﬁg. 1). In all patients,
repeated urine samples were tested, and the abnor-
mal pattern was consistently observed. Quantitation of
amino acids with a free a-amino group (reacting with
ninhydrine) in serum/plasma and urine revealed no ma-
jor abnormality. Only limited family studies were pos-
sible; metabolite patterns of urine of the parents from
family OS-127 and of the unaffected brother OS-104 II-
2 were unremarkable. In family OS-120, only themother
could be analyzed, and her urine showed a normal me-
tabolite pattern.
The characteristic pattern of N-acetylated amino
acids initially found by GC-MS was corroborated by
NMR spectroscopy of all four patients’ urine samples
(table 1). In addition, increased levels of the metabolites
N-acetylglutamine, N-acetylasparagine, N-acetylserine,
and N-acetylthreonine were found by NMR spectros-
copy. These metabolites were not detected by GC-MS
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Figure 2 Assessment of ACY1 activity in lymphoblasts of 3
patients (OS 104 II-1, OS 124 II-1, and OS 127 II-1) and of 19 controls
revealed much lower enzyme activity in the patients’ cells (P p .001
in Student’s t test).
Table 1
Concentrations of N-Acetylamino Acids in Urine, as Quantiﬁed by 1H-NMR Spectroscopy
METABOLITE
CONCENTRATION IN URINE OF INDIVIDUALa
(mmol/mol creatinine)
OS-104 II-1
OS-127 II-1 OS-124 II-1 OS-120 II-1Sample 1 Sample 2 Sample 3
N-acetylalanine 93 115 91 69 312 156
N-acetylasparagine 89 79 66 155 356 133
N-acetylglutamic acid 193 186 169 281 741 284
N-acetylglutamine 111 98 86 148 526 143
N-acetylisoleucine 18 23 !10 58 40 30
N-acetylglycine 108 125 92 175 429 515
N-acetylvaline !10 !10 !10 30 ND ND
N-acetylserine 104 111 99 !10 393 208
N-acetylthreonine 18 23 17 !10 41 28
N-acetylmethionine 41 45 46 80 75 50
NOTE.—In addition to the listed metabolites, N-acetylleucine was always detected but—because of in-
terferences—was difﬁcult to quantify. Futhermore, an unidentiﬁed N-acetyl compound, with the chemical
shift 2.108 ppm for HNiCOiCH3, was found. In control urine samples, concentrations of N-acetylated
amino acids are !40 mmol/mol creatinine.
a ND p not detected.
following our standard derivatization procedure with
diazomethane. In plasma/serum samples of all three in-
dividuals studied in this regard (OS-104 II-1, OS-124 II-
1, and OS-127 II-1), NMR spectroscopy yielded no de-
tectable N-acetylated amino acids.
Enzyme Assays
ACY1 activity was assessed in EBV-transformed lym-
phoblasts of patients from families OS-104,OS-124, and
OS-127 and of 19 controls. The results clearly demon-
strate decreased enzyme activity of the patients’ cells
(0.08, 0.07, and 0.04 nmol min1 mg1) compared with
the control values (mean 1.24 nmol min1 mg1; SD 0.53
nmol min1 mg1) (ﬁg. 2).
Patients
Three of the four ACY1-deﬁcient individuals had been
ascertained by the presence of N-acetylamino acids in
their urine in the course of selective screening for inborn
errors of metabolism. The fourth patient had biotinidase
deﬁciency detected by newborn screening, and the N-
acetylamino aciduria was detected in the course of or-
ganic acids analysis to follow up his ﬁrst diagnosis.
OS-104 II-1 is the eldest child of consanguineous
Turkish parents residing in Germany. Two younger
brothers are unaffected. The boy’s cognitive develop-
ment appears normal. At present, he attends high school.
He started walking at age 1 year. At age 3 years, the
parents ﬁrst observed muscle weakness that prompted a
thorough investigation at age 11 years. During that ex-
amination, the boy presented with low-normal muscle
tone and a shambling gait. Ultrasound, electromyogra-
phy, and NMR tomography of the musculature from
the lower extremities showed unremarkable results. In
addition, routine histological, histochemical, enzyme
histochemical, and immunohistochemical studies of a
biopsied specimen from the left quadriceps muscle did
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Figure 3 Results of the mutational analysis of ACY1 in four patients with ACY1 deﬁciency. A, Sequence chromatograph from the affected
individual OS-124 II-1 and his consanguineous parents (father, OS-124 I-1; mother, OS-124 I-2), showing a homozygous GrA transversion at
position 1 of the obligatory exon 6 splice-acceptor site [IVS51GrA] in the patient and heterozygous mutations in both parents, consistent
with homozygosity by descent. B, Sequence chromatograph from a control individual and the affected individual OS-104 II-1, depicting a
homozygous 2-bp insertion in exon 15 resulting in a frame shift [1105^1106insAC] and a postmature stop codon [369PfsX46].C, Two sequence
chromatographs of the affected individual OS-120 II-1 depicting her compound heterozygous missense mutations 699ArC in exon 10 (E233D)
and 1057CrT in exon 14 (R353C), which predicts the substitutions of evolutionary conserved amino acid residues E233D and R353C,
respectively. D, Sequence chromatograph from the affected individual OS-127 II-1, showing the homozygous missense mutation 1057CrT in
exon 14 (R353C).
not reveal any signiﬁcant myopathological abnormali-
ties (H. H. Goebel, University of Mainz, Germany; see
Acknowledgements).
OS-127 II-1 is the ﬁrst child of healthy, nonconsan-
guineous German parents. The boy was identiﬁed in a
general neonatal screening as being biotinidase deﬁcient,
for which he is currently being given treatment with 5
mg biotin/d. Under this medication, his cognitive and
motor skills have developed completely normally up to
his current age of 17 mo.
OS-124 II-1 is the second child of consanguineous
Turkish parents. He has a healthy older sister. Because
of early impaired psychomotor development character-
ized by markedly disturbed central coordination and low
muscle tone, magnetic resonance imaging of the head
and spine was performed at age 3 mo, after cerebellar
hypoplasia had been suggested prenatally by sonogra-
phy. Cranial imaging demonstrated hypoplasia of the
corpus callosum and the vermis cerebelli, as well as de-
layed myelination of the supratentorial white matter.
The lumbar spinal cord exhibited a syringomyelia with
a length of 3.5 cm.
OS-120 II-1 is the daughter of healthy parents of
German (mother) and Italian (father) origin. Her youn-
ger brother is healthy. At age 2 years, a neuropediatric
evaluation was initiated because of moderate retarded
cognitive and motor development.
Mutation Analysis
Molecular analysis detected ACY1 mutations in all
four individuals with an increased urinary excretion of
N-acetylated amino acids suggestive of ACY1 dysfunc-
tion (ﬁg. 3). Consistent with parental consanguinity, two
patients had homozygous mutations. In individual OS-
124 II-1 we detected a homozygous obligatory splice-
site mutation (IVS51GrA) predicting malfunction of
the acceptor splice-site from exon 6. This mutation
(IVS51GrA) predicts the skipping of exon 6 (amino
acid residues 121 to 146) and a premature stop codon
(ﬁg. 2A). Segregation analysis showed that both parents
(OS-124 I-1 and I-2) were heterozygous for this muta-
tion. Individual OS-104 II-1 was homozygous for a 2-
bp insertion (1105^1106insAC) predicting a frame shift
beginning with amino acid residue 369. Notably, the
mutation does not lead to premature termination of
translation but predicts a C-terminal mutated protein
(369PfsX46) that is longer than the wild-type protein
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(408 amino acid residues) and affects the C-terminal
peptidase domain (ﬁg. 3B). Segregation analysis con-
ﬁrmed heterozygous carrier status in both parents (OS-
104 I-1 and I-2). Child OS-120 II-1 was compound
heterozygous for two missense mutations, 699ArC
(E233D) and 1057CrT (R353C) (ﬁg. 3C). Mutation
1057CrT (R353C) was transmitted from the mother;
DNA from the father was not available. Both missense
mutations (E233D and R353C) predict the substitution
of amino acid residues located in the large peptidase
domain (ﬁg. 4) that has been evolutionary conserved in
Mus musculus (mouse), Rattus norvegicus (rat), Xeno-
pus laevis (frog), and Danio rerio (ﬁsh). Proband OS-
127 II-1 was homozygous for missense mutation
1057CrT (R353C). The parents are not known to be
consanguinous. Sequence analyses revealed that they are
both heterozygous carriers of the 1057CrT mutation
(ﬁg. 3D). The E233D missense mutation was absent
from 210 control chromosomes. The R353C sequence
variant was identiﬁed in 1 of the 210 chromosomes of
the control cohort.
Northern Blot Analysis
The expression pattern of the human ACY1 gene was
determined using human multiple-tissue northern blots
(ﬁg. 5). The ACY1 probe detected a single band of the
expected size of ∼1.6 kb, consistent with the previously
reported size of the human cDNA (Cook et al. 1993).
The highest expression level was detected in kidney.
ACY1 expression was moderately high in brain and was
weaker in placenta, spleen, uterus, and lung, as reported
elsewhere (Cook et al. 1993). In addition, we detected
expression in prostate, testis, small intestine, and
colon, tissues that have not been previously studied (data
not shown). We found no indication for alternative
transcripts.
Discussion
Enzyme assays conﬁrmed ACY1 deﬁciency in cells of
individuals with N-acetylamino aciduria. Therefore, we
searched for mutations in theACY1 gene in four affected
individuals belonging to families from Turkey, Germany,
and Italy. On the basis of the pedigrees with unaffected
parents and consanguinity in two families (OS-104 and
OS-124), autosomal recessive inheritance was assumed.
Sequence analysis in affected children of these families
identiﬁed homozygous loss-of-function mutations pre-
dicting abnormal splicing in OS-124 II-1 (IVS51GrA)
and aberrant translation in OS-104 II-1 (1105^
1106insAC), compatible with homozygosity by descent.
In the other two families, homozygous (OS-127 II-1 and
R353C) and compound heterozygous (OS-120 II-1,
R353C, and E233D) missense mutations were identiﬁed,
predicting the substitution of evolutionary conserved
amino acid residues. To exclude rare polymorphisms,
210 control chromosomes were checked for the presence
of the missense mutations and yielded negative results
for E233D. Interestingly, we found one R353C allele in
the control population, which is consistent with a rare
polymorphism or a more common mutation. This is in
line with the identiﬁcation of this sequence variant in
two of four individuals with ACY1 deﬁciency. The en-
zyme activity test has shown the functional relevance of
harboring this mutation in both of them. Altogether, we
clearly demonstrated that recessive ACY1 mutations are
responsible for the distinct urinary metabolic proﬁle con-
sistent with ACY1 dysfunction. Interestingly, mutations
could be identiﬁed in all individuals with elevated con-
centrations of several N-acetylamino acids. Thus, we
have no indication for genetic heterogeneity. Segregation
analyses revealed that all parents studied were hetero-
zygous carriers of the mutations. Urine analyses in par-
ents yielded normal results, conﬁrming recessive trans-
mission of ACY1 deﬁciency.
Next, we asked whether ACY1 deﬁciency is related
to the observed clinical phenotypes in the reported pa-
tients or merely represents a biochemical abnormality.
The organic acids analysis that led to the detection of
the ACY1-deﬁcient individuals is part of selective screen-
ing for inborn errors of metabolism, which is not per-
formed routinely in healthy children but only in indi-
viduals in whom a metabolic disease is considered. This
results in a strong bias. To further clarify this, studies
of family members would be advantageous. However,
this was not possible in the family cohort we studied.
The clinical presentation of the four patients is hetero-
geneous: (i) mild psychomotor retardation, (ii) moderate
psychomotor retardation and brain and spinal cord mal-
formations, (iii) muscle weakness but normal cognitive
development, and (iv) the unremarkable clinical course
of a biotinidase-deﬁcient and early treated boy. This phe-
notypic variability does not support ACY1 deﬁciency
being a disease.
However, the protein sequence of ACY1 is conserved
between ﬁsh, frog, mouse, rat, and human, supporting
an evolutionary conserved role in physiology. Strong ex-
pression of the human gene and its mouse orthologAcy1
in brain, liver, and kidney suggest a role of the enzyme
in amino acid metabolism of these organs.
Our ﬁnding of ACY1 expression in the kidney, which
is consistent with previous observations (Cook et al.
1993; Lindner et al. 2000), is also in line with a possible
functional role of ACY1 in recycling of N-acetylated
amino acids in the kidney, which can explain the highly
elevated concentrations of N-acetylated amino acids in
the urine of the four children harboring ACY1 muta-
tions. Thus, in the case of severe dietary protein restric-
tion, ACY1 dysfunction might contribute to reduced
Figure 4 Sequence alignment of human ACY1 and corresponding orthologs from various species. Highlighted letters and letters on a
gray background represent identical and conserved amino acid residues, respectively. Most parts of the orthologous proteins are highly conserved
between species and predict a large peptidase domain, which includes a central peptidase dimerization region. Human ACY1 shares amino acid
sequence identity and similarity, respectively, with M. musculus (85%/91%), R. norvegicus (87%/93%), X. laevis (60%/76%), and D. rerio
(61%/77%). The amino acids affected by the missense mutations (E233D and R353C) are marked with arrows. The obligatory acceptor splice-
site mutation [IVS51GrA] is marked with an asterisk (*) and predicts the skipping of exon 6 (aa 121 to aa 146) and a premature stop codon
[120QfsX1]. The 2-bp insertional mutation [1105^1106insAC] is marked with an arrowhead and predicts a frame shift leading to a severely
altered C-terminus [369PfsX46]. Ortholog proteins were identiﬁed by BLAST search. The multiple-protein alignment was constructed using
the MAP program. Functional domains were predicted with the Scansite program. The corresponding accession numbers of the protein sequences
are: Homo_sapiens AAH14112, Mus_musculus AAH05631, Rattus_norvegicus AAH78930, Xenopus_laevis AAH77639, and Danio_rerio
NP_957289.
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Figure 5 Human adult tissue northern blot of the ACY1 gene.
The ACY1 probe detects a single band of ∼1.6 kb, which corresponds
to the predicted size of the human cDNA. Expression is highest in
kidney, strong in brain, and weaker in placenta and spleen. ACY1
mRNA is also expressed in uterus and lung. RNA size markers are
indicated on the left side.
availability of amino acids due to impaired amino acid
salvage. This could be a disadvantage during periods of
profound catabolism or starvation. In addition, ACY1
deﬁciency could possibly result in accumulation of acet-
ylated amino acids in analogy to N-acetylaspartic acid
in aminoacylase 2 deﬁciency (Canavan disease).
ACY1 may also have functions beyond the deacyla-
tion of amino acids. It has been known since 1881 that
ACY1 can also serve as a catalyzer for acylation reac-
tions—for instance, forming hippuric acid from glycine
and benzoic acid (Schmiedeberg 1881). However, classic
benzoate detoxiﬁcation is achieved by a different mech-
anism, involving mitochondrial glycine conjugation.
Therefore, Lindner et al. (2000) suggested that ben-
zoylglycine (hippuric acid) synthesis, catalyzed by
ACY1, may represent an alternative benzoate detoxiﬁ-
cation pathway. The main source of benzoic acid orig-
inates from plant-derived food rich in aromatic com-
pounds. During human evolution, the proportion of
animal-derived food increased at the expense of plant-
derived food; in other words, humans changed from her-
bivores to omnivores. Thus, ACY1-dependent detoxiﬁ-
cation of benzoic acid may have been an advantage prior
to this transition and might still be beneﬁcial in vege-
tarians. Interestingly, ACY1 also participates in drugme-
tabolism. For example, aminoacylase activity is involved
in the metabolism of mercapturates, which are formed
from drugs such as paracetamol (Anders and Dekant
1994).
It is possible that ACY1 deﬁciency has consequences
later in life, perhaps as a predisposing factor or modiﬁer.
It should be noted that long-term follow-up studies with
a greater number of individuals may be required to de-
tect such effects; observations on the basis of four pe-
diatric patients alone may not be sufﬁcient.
Although the identiﬁcation of “novel” inborn errors
of metabolism may reveal pathways and reactions that
had gone unnoticed, ACY1 activity was described by the
German physician Oswald Schmiedeberg 124 years ago
(Schmiedeberg 1881) but was never placed in the context
of a genetic disorder. The observation of ACY1-deﬁcient
humans offers the opportunity of learning more about
the physiological role of ACY1. Awareness of the ex-
istence of this genetic entity may lead to the identiﬁcation
of more cases, and their follow-up may clarify whether
ACY1 deﬁciency is a disease or a biochemical variant.
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Web Resources
URLs for resources presented herein are as follows:
BLAST, http://www.ncbi.nlm.nih.gov/blast/ (used to identify ortholog
protein sequences and to establish the genomic organization of
ACY1)
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for cDNA and
genomic sequences of ACY1 [accession numbers BC014112 and
NT_022517.17])
MAP, http://searchlauncher.bcm.tmc.edu/multi-align/multi-align.html
(used to construct multiple-protein alignment)
RZPD Web site, http://www.rzpd.de
Scansite, http://scansite.mit.edu/ (used to predict functional domains)
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